GlassScriptPhysician profile
Arpit Kiranbhat Patel
NPI 1194074591
$2,761.09
in general payments reported to CMS, 2019-2025
25 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $318 · 2021: $352 · 2022: $429 · 2023: $359 · 2024: $507 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $533.65 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $507.04 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| Novo Nordisk INC | $496.39 | 2021-2025 | Wegovy, Ozempic |
| Amgen INC. | $201.44 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $144.83 | 2019-2024 | Camzyos, Eliquis |
| Heartflow, INC. | $123.53 | 2025 | |
| Kestra Medical Technology Services, INC. | $106.40 | 2022-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $102.60 | 2022-2024 | Verquvo |
| Pfizer INC. | $98.53 | 2019-2024 | |
| Amarin Pharma, INC. | $80.86 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $73.44 | 2020-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $40.86 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $39.50 | 2019-2020 | |
| Scpharmaceuticals INC. | $34.52 | 2024 | |
| Lantheus Medical Imaging, INC. | $24.65 | 2023 | Definity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $20.82 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.57 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.22 | 2024 | Onpattro |
| Covidien LP | $15.53 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.89 | 2020 | |
| Gilead Sciences, INC. | $13.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.40 | 2022 | |
| Bardy Diagnostics, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arpit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.